Drug Search Results
More Filters [+]

TG-103

Alternative Names: tg-103, tg 103, tg103
Latest Update: 2024-02-14
Latest Update Note: Clinical Trial Update

Product Description

CSPC is developing tg-103, a subcutaneous agent for Type 2 Diabetes

Mechanisms of Action: GLP-1 Agonist

Novel Mechanism: No

Modality: Fusion Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: CSPC
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TG-103

Countries in Clinic: China

Active Clinical Trial Count: 12

Highest Development Phases

Phase 3: Obesity|Overweight|Type 2 Diabetes

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SYSA1803-010

P3

Not yet recruiting

Type 2 Diabetes

2026-03-01

63%

SYSA1803-009

P3

Not yet recruiting

Type 2 Diabetes

2026-03-01

63%

SYSA1803-013

P3

Not yet recruiting

Overweight|Obesity

2025-01-31

57%

SYSA1803-017

P2

Not yet recruiting

Obesity|Overweight

2024-12-20

24%

Recent News Events